tirzepatide for the treatment of obstructive sleep apnea and obesity FDA has just approved Zepbound (tirzepatide), the first medication designed to treat both apnoea (OSA) simultaneously. In clinical trials, Zepbound helped reduce breathing disruptions by 50% and Tirzepatide - A New Dawn

Rodent studies [11, 56] have shown that central or peripheral administration of GLP-1R agonists reduces short-term food and water intake and lowers body weight

Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Korn S, Lachin JM, McGuire DK, Pencina MJ, Standl E, Stein PP, Suryawanshi S, Van de Werf F, Peterson ED, Holman RR, TECOS Study Group

Youll have access to continuous support, including regular check-ins and professional advice, to keep you on track

This is a normal response to semaglutide and can help you make healthier food choices and control portion sizes

The blue area of the paper tab should only show the lot number